Synergies, tensions and challenges in HIV prevention, treatment and cure research : exploratory conversations with HIV experts in South Africa by Moodley, Keymanthri et al.
RESEARCH ARTICLE Open Access
Synergies, tensions and challenges in HIV
prevention, treatment and cure research:
exploratory conversations with HIV experts
in South Africa
Keymanthri Moodley1,4*, Theresa Rossouw2, Ciara Staunton1 and Christopher J. Colvin3
Abstract
Background: The ethical concerns associated with HIV prevention and treatment research have been widely
explored in South Africa over the past 3 decades. However, HIV cure research is relatively new to the region and
significant ethical and social challenges are anticipated. There has been no published empirical enquiry in Africa
into key informant perspectives on HIV cure research. Consequently, this study was conducted to gain preliminary
data from South African HIV clinicians, researchers and activists.
Methods: In-depth interviews were conducted on a purposive sample of fourteen key informants in South Africa.
Audiotaped interviews were transcribed verbatim with concurrent thematic analysis. The perspectives of HIV clinicians,
researchers and activists were captured. Analyst triangulation occurred as the data were analysed by three
authors independently.
Results: The rapid evolution of HIV cure research agendas was prominent with participants expressing some
concern that the global North was driving the cure agenda. Participants described a symbiotic relationship
between cure, treatment and prevention research necessitating collaboration. Assessing and managing
knowledge and expectations around HIV cure research emerged as a central theme related to challenges to
constructing ‘cure’ - how patients understand the idea of cure is important in explaining the complexity of cure
research especially in the South African context where understanding of science is often challenging. Managing
expectations and avoiding curative misconception will have implications for consent processes. Unique strategies
in cure research could include treatment interruption, which has the potential to create therapeutic and ethical
conflict and will be perceived as a significant risk. Ethical challenges in cure research will impact on informed
consent and community engagement.
Conclusions: It was encouraging to note the desire for synergy amongst researchers and clinicians working in the
fields of prevention, treatment and cure. Translation of complex HIV cure science into lay language is critical. Moving
forward, RECs must be adequately constituted with scientific expertise and community representation when reviewing
cure protocols. It is hoped that knowledge and resource sharing in the context of collaboration between research
scientists working in cure and those working in treatment and prevention will accelerate progress towards cure.
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Background
South African health researchers and clinicians have been
actively involved in HIV research for more than three de-
cades with a focus on prevention and treatment [1–3]. Na-
tionally and internationally, associated ethical challenges in
prevention and treatment have been widely debated [4–7].
HIV cure research is now advancing rapidly in Europe and
the United States with the exploration of various scientific
strategies including early treatment of acute infection, neu-
tralizing antibodies, gene therapy, therapeutic vaccines or a
combination of approaches [8, 9].
While the ethical challenges with HIV treatment and
prevention research have dominated the discourse to date,
there has been a growing focus on the ethical challenges
of HIV cure research in recent times. Lo and Grady have
highlighted key ethical issues to consider in conducting
cure research including informed consent, fair selection of
participants, social value, scientific validity, favourable
risk-benefit ratio, independent review, respect for partici-
pants and communities and collaborative partnership [10].
Sugarman has expanded on these to include risk to part-
ners, confidentiality and financial conflicts of interest. He
adds the importance of ethical oversight by Research
Ethics Committees (REC), rigorous consent processes and
empirical data on consent and trial design [11]. Other
authors have emphasized the conceptualisation of cure
[12–14] and the challenges in ensuring adequate informed
consent for HIV cure trials [15]. Given the wide range of
illegitimate “cures” marketed in Africa historically, mis-
conceptions about cure are likely to cloud understanding
of cure in consent processes [16–29]. Scientifically, the
distinction between a sterilizing cure (a cure that com-
pletely removes the disease from the body and renders the
patient symptom free) and a functional cure (a cure that
controls the symptoms without eliminating the virus) adds
to the challenge of understanding cure [13, 14].
Given the complexity of HIV cure science and the wide
range of stakeholders involved (HIV infected individuals,
HIV clinicians, researchers, REC members, policy makers,
HIV experts, health economists, health funders, the
pharmaceutical industry and the media), informed consent
processes for cure research in South Africa are likely to be
challenging. It is therefore important to elicit multiple per-
spectives of a wide range of stakeholders in South Africa
to inform consent processes that will be critical in the re-
cruitment and enrolment of potential participants. There
have been calls for biomedical scientists to collaborate
with social scientists to develop decision-making studies
as they can provide important information on perceptions
of cure in real time [30]. The experiences from HIV vac-
cine and prevention studies highlight the importance of
early stakeholder engagement in managing participant
expectations as well as in helping to mitigate trial failures
[31]. In HIV prevention and treatment research to date
the science has sometimes progressed ahead of important
social, behavioural and ethical concerns leading to unex-
pected or negative results [32–37]. The importance of early
stakeholder engagement to explore the complex web of
ethical and social concerns related to HIV cure science has
therefore been emphasized [38]. To date, there have only
been three empirical publications globally on stakeholder
perspectives around HIV cure research: an Australian study
involving patients only [39], a study from China that mainly
examined the perspectives of injection drug users [40] and a
South African study that elicited preliminary views of
diverse healthcare providers and a few patients at an HIV re-
search clinic in Cape Town [41].
This study reflects insights from key informants (HIV ex-
perts) who have been working in the field of HIV/AIDS in
South Africa over the past three decades. It is the first em-
pirical investigation conducted to gain preliminary data
from HIV clinicians, researchers and activists to guide
future phases of a larger multisite HIV cure project on re-
lated ethical and social issues where the views of other
stakeholders involved in HIV cure research, including HIV-
infected individuals, will be elicited.
Methods
The perspectives of three groups of participants—research-
ers working in treatment and prevention, HIV clinicians
and HIV activists—were elicited. The methodological ap-
proach adopted in this study is based in constructivist the-
ory [42]. We conducted in-depth interviews with 14 South
African stakeholders, including HIV clinicians, researchers,
policymakers and activists in Cape Town, Johannesburg,
Pretoria and Durban (South Africa) after obtaining in-
formed consent. Interviews lasted 60 min. The demograph-
ics of those interviewed are as follows:
Key Informant Profession Gender Sector
Key informant A Researcher Female Public
Key informant B Clinician Male Private
Key informant C Activist Male N/A
Key informant D Policymaker Male Public
Key informant E Researcher Female Public
Key informant F Researcher Male Public
Key informant G Researcher Male Public
Key informant H Researcher & clinician Male Public
Key informant I Researcher Female Public
Key informant J Researcher & clinician Female Public
Key informant K Researcher & clinician Male Public
Key informant L Researcher Male Public
Key informant M Social scientist Male Public
Key informant N Social scientist Male Public
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Recorded interviews were transcribed verbatim with
concurrent thematic analysis. In addition, both inter-
viewers (CC and TR) and the principal investigator
(KM) read through the transcripts to extract themes
(analyst triangulation). The data were analysed by three
authors independently and then integrated via discus-
sion. This study was approved by the Research Ethics
Committees at Stellenbosch University (N13/05/063),
the University of Pretoria (29/2015) and the University
of Cape Town (761/2014).
Results
The findings below synthesize key informant views on
the important social and ethical considerations related
to HIV cure research in South Africa. They are orga-
nized into five sections, each addressing a different di-
mension of cure research.
Evolution and drivers of HIV cure research
An important part of the broader social and ethical con-
text for HIV cure research involves the organization,
funding and governance of this area of research, from
global through to local levels. There was broad agree-
ment among our participants that cure research is cur-
rently driven by Northern funders and researchers,
largely as a result of stronger capacity, more resources,
and better laboratory infrastructure required for the
current forms of cure research. Research on HIV cure is
only now getting underway in South Africa and appears
to be driven largely by work in virology and immunology
as well as some early efforts to test the effectiveness of
early infant antiretroviral treatment (ART).
With respect to the funding sources for HIV cure re-
search, participants reported little investment at this
stage by the private sector (whether pharmaceutical
companies or private biomedical research institutes).
Instead, they indicated that the National Institutes of
Health and philanthropic foundations in the global
North were the main actors currently funding this
stream of research.
“Among others it will be mostly NIH in the US and …
maybe even the Gates foundation ….”
Participants noted that the total amounts of funding
for cure research were still quite small in comparison to
research funding for HIV prevention and treatment re-
search. There was some concern, though, that most of
the funding, and thus most of the research direction-
and priority-setting, was being driven by American and
European researchers and funders.
Participants, however, did not express specific con-
cerns that this was steering cure research in one direc-
tion or another. While the general sense was that the
lack of close pharmaceutical industry involvement at this
early stage of cure research was probably appropriate,
one participant noted that a weakness in much of the
biomedical prevention research for HIV (e.g. microbicide
gels) is that it often took place without substantive in-
volvement of industry, and this in turn represented a
threat to quick and sustainable scale-up in the event that
effective solutions were found.
Despite the many possible paths to either a functional
or sterilizing cure, most participants described HIV cure
research as a fairly ‘unified field’ with little direct compe-
tition for funding and few serious debates over the most
promising directions for research. Several argued that
this was largely a result of the newness of the field and
the limited size of available funding. There was a con-
sensus among the researchers we interviewed that un-
derstanding the characteristics of the HIV ‘reservoirs’ in
the body, as well as the ways they related to both latent
(whereby the virus remains in the resting CD4+ T cells)
and active infection, was a key research priority [43].
The role of the International AIDS Society (IAS) and
its HIV Cure Working Group was noted by several par-
ticipants as being a key shaper and driver of the field of
HIV cure research. None of the participants raised con-
cerns about the role of the IAS except to note that again,
it was an organization that, in their view, had an over-
representation of Northern actors and thus risked privil-
eging their agendas and perspectives.
HIV Cure research and the broader research and practice
context
Part of understanding the social and ethical context for
HIV cure research involves also considering how cure
research is situated within broader research and practice
contexts. For example, we asked participants about how
they understood the relationships—and potential syner-
gies and tensions—between HIV cure research and other
forms of HIV research such as vaccine development or
treatment research. There was a consensus among the
researchers that cure research built on existing know-
ledge bases but that it also in turn extended knowledge
in these other fields of inquiry. One participant noted
the ways in which early cure research work on HIV res-
ervoirs (“a cell type or anatomical site that allows per-
sistence of replication-competent HIV-1 for long periods
of time in patients on optimal HAART regimens”) had
provided important insights for vaccine researchers [43].
“I do think focusing on cure does assist us in
understanding the cellular machinery … and
certainly the vaccine people are looking at all of
this with a huge amount of interest… how do you
get the virus out of the cell, what is the
immunology that controls things…” .
Moodley et al. BMC Medical Ethics  (2016) 17:26 Page 3 of 11
At the same time, there was excitement that research
into the HIV reservoir and other novel aspects of cure
research (such as therapeutic vaccines, broadly neutraliz-
ing antibodies, and stem cells) promised to deliver new
basic science insights as well. There was a sense overall
that cure research would bring wider scientific benefits
even if a cure proved elusive in the long run:
“I can only see positive things, such as capacity
building… the establishment of a gene therapy platform
that will be useful for other purposes going forward.”
We also asked participants about how the ‘cure
agenda’ fits into the current landscape of treatment and
prevention programming. We were interested in under-
standing if they anticipated conflicts around funding and
prioritization within health service and research policies
and budgets. Again, as noted above, there was a widely
shared sense that given its current small scale, cure re-
search was not yet perceived as a threat to the recogni-
tion and funding for treatment and prevention. Several
participants did assert, however, that decisions around
funding and priorities would always be difficult and in-
volve trade-offs and a balancing of priorities.
“So long as money from implementation is not diverted”
“Yes, well I think the overlapping concern could be
that it will take money away from other…important
research and programmatic areas… I think that’s an
ongoing debate in the field”
Several participants noted, though, that regardless of
the potential tensions between prevention, treatment
and cure agendas, it was critical to also think about pre-
vention, treatment and cure as always existing in relation
to each other. Two points were made in this vein. First,
there is a complex tension between the three domains
right now. HIV treatment has been remarkably effective
but is of increasingly uncertain sustainability especially
in light of the recent Strategic Timing of Anti-Retroviral
Treatment (START) trial that recommends antiretro-
viral treatment for all HIV infected persons regardless
of CD4 count [44]. Prevention is thus increasingly rec-
ognized as critical in the long run for turning the tide
but current behavioural and biomedical interventions
to reduce incidence have been promising on paper but
disappointing in practice.
“The chances are though, you know, it’s [a cure is]
going to be expensive initially, it’s probably going to be
relatively complicated, it’s probably going to have some
side effects. So my sense is not to get the virus in the
first place… You know what we know via the sciences
that there is a lot of damage done in the first few
weeks of the infection… I think it is difficult to
imagine that getting a cure will outweigh prevention
in the first place.”
There was a consensus that cure was therefore a crit-
ical goal to integrate into the HIV landscape but that a
safe, effective and affordable cure was also likely to be a
very long way off.
Second, several participants noted that even if such a
cure were to be developed, it is very likely that the need
for all three interventions—prevention, treatment and
cure—would persist into the future.
“In terms of the HIV research, to a large extent, what
we need to be doing is buckling down, finding people
who are HIV-infected and doing what we can to ensure
they can take their medicines for the rest of their lives.
… We’ve got good enough medicines. If we could find
everyone and treat everybody, we would be able to
start seeing a decline in incidence… Research in HIV is
slowing down, because it is now implementation we
need to be doing.”
Just as for cancer or TB or any number of other
diseases, an HIV cure was not seen as a replacement
for treatment and prevention programs but rather as
an adjunct.
Assessing and managing knowledge and expectations
around HIV cure research
When asked to assess what individual and community
expectations might be around HIV cure research, and
how these might be managed, most of our participants
initially pointed to widespread enthusiasm about the
possibility of a cure, an interest that was generally stoked
by media accounts of widely-known cases such as the
‘Berlin patient’ or the ‘Mississippi baby’. When asked in
more detail, however, how they thought patients and
communities would respond to some specific cure re-
search scenarios, the picture they painted was more
mixed. They argued that cure research would likely
focus on recruiting people with HIV infection and thus
people with an interest in making use of highly effective
ART services. They felt that some people who were
stable on treatment and virally suppressed may be reluc-
tant to tamper with this success for research studies
unlikely to benefit them.
“If it’s not broken, why fix it?”
“People just need to understand that they are taking a
significant risk. If they stop it [antiretroviral treatment],
the virus may come back and do harm.”
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Although HIV experts expressed concern over the
possible reluctance of participants to risk interrupting
treatment that is working, this concern was raised by
patients themselves as well as healthcare workers in an
earlier study [42]. We believe that this is a valid concern.
There was also concern about the knowledge of and
counselling required for participants in order to conduct
this kind of research ethically. There was consensus that
medical research like this always requires careful prep-
aration and engagement at both individual and commu-
nity levels, and that doing this well was complex but
possible. Some difference of opinion emerged, however,
about how easy this process of preparation might be.
Clinical trialists working in well-resourced and well-
managed research sites were generally confident and
described this kind of engagement, education and
counselling as routine.
“You know good community engagement means that
you understand your community you understand
who your stake holders are and who your gate
keepers are and that you engage in the continuous
process and so, it’s community awareness, it’s
community mobilization, it’s community
engagement, and it’s community presentation and
then it’s dissemination of information.”
Activists, social scientists and doctors working in the
public sector were, however, less confident that this
could so easily be achieved without careful planning and
adequate resourcing and oversight.
“Which is why I think that the Community Advisory
Board; because we really do try and draw from broad
spectrum of people within the communities that we serve,
would be a safer way of being able to communicate the
message. Because we would start off with science based
education on why cure is so difficult; and what the issues
are. And then you know let them disseminate within their
own communities.”
“I think it’s really understanding … what the intention
is; or the goal of the study is, if that is explained well
and …as well as possible so it shouldn’t be a rushed
process and, and luckily many times there are
communities where this is done and they deliberately
find a systematic way of engaging with communities to
prepare them before the treatment starts so if that is
done that could be important in getting support from
communities”.
One particular concern shared by all, however, was
around the notion of the reservoir and ‘latent’ HIV in-
fection and the potential difficulty people might face in
understanding these concepts and the ways research
studies were investigating them. The fact that the HI
virus can persist within the body, and even be integrated
into the genomes of individual cells, has not been part of
the widespread HIV awareness campaigns in South
Africa, and is not a widely known medical fact. We be-
lieve that lay explanations of the notion of reservoirs
would be critical in consent documents and processes.
Similarly, several participants noted that it was critical
to avoid the therapeutic misconception in cure research
and to also, more generally, prepare research partici-
pants as well as research staff and affected communities
for the inevitability of frequent failure and even the po-
tential for harm. Participants wanted to ensure that the
current enthusiasm around cure research, and the recent
successes of ART research and services, did not lull
those involved into a false sense of confidence.
“The last thing you want to do is for someone to trust
in something that has not yet been proven.”
“From a psychological point of view, I would say that
the biggest risk that we face is raising people’s hope
and then not being able to meet that, so that we create
false expectations that we can’t meet and people
become disillusioned”
Finally, an important difference in the social and eth-
ical dimensions of cure research, as opposed to treat-
ment and prevention research, emerged in participants’
recognition during these interviews that activists, com-
munities, and civil society groups have had very little
involvement so far in developing, driving and shaping
the cure research agenda. This is in stark contrast to the
unique and profound ways in which HIV treatment and
prevention research included the voices of people living
with HIV, albeit sometimes reluctantly, over the last
three decades [45]. Participants expressed some ideas as
to why this difference might be—specifically relating to
the normalisation of HIV—but there was also some con-
cern that this represented a potential threat to the eth-
ical conduct of cure research in the long run.
Challenges to constructing ‘cure’
All of our conversations with participants around HIV
cure research included reflections, often extended ones,
on the complexity and instability of the concept of ‘cure’:
“What does a cure mean? Does it mean that I’m free of
the disease and I never have to take pills; and I never
have to go and see the doctor ever again? Or does it
mean that somehow I’m controlling the virus? I think
that that might be one of the issues where we differ from
what patients may think the cure is going to mean.”
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There were a number of ways in which participants
tried to capture these nuances. We have synthesized
these under five main sub-themes.
A spectrum of cure(s)
Participants all noted the critical distinction made in the
current HIV cure discourse between ‘sterilizing’ and
‘functional’ cures, a distinction that was described by
several of the researchers as a new and helpful way to
think more complexly about cure. Some stated that they
had not taken cure research seriously as a fruitful re-
search avenue until they were introduced to the idea of
a functional cure that would suppress replication of the
virus over the long term without fully eliminating it
from the body:
“For me, ‘functional cure’ was a transition in the way I
started to think about the value of cure research”.
Once they had accepted the notion of a ‘functional’
cure for HIV, however, several participants went on to
argue that medium- to long-term viral suppression with-
out ART but following an intensive period of ART (with
treatment re-initiation after recurrence) could also be
considered a form of serial functional cure. There was
even a suggestion by one participant that one could see
standard ART itself as a cure, in that it effectively sup-
pressed the virus and allowed the immune system to re-
constitute itself. He added that this was, pragmatically
speaking, one form of cure that many people may be
reluctant to give up for participating in research with
uncertain personal benefits.
A long and uncertain pathway to cure
There was also recognition that cure research—involving
whatever form of cure one might imagine—would
almost inevitably have to pass through many years of
weakly and partially effective cures, unstable cures,
harmful cures, and cures that continued to result in
some degree of pathology (e.g. functional cures that
didn’t fully suppress chronic inflammatory responses).
All of these constructions of cure challenged the simple,
conventional notions of cure as something that simply
eliminates the infection from the body.
There was a related concern expressed by several par-
ticipants about the labelling of research along this path-
way as ‘cure’ research. They thought that it might be
important to avoid mention of the term ‘cure’ when pos-
sible and use more limited and specific concepts such as
remission, suppression, and control.
“For patients there are various specific connotations,
meaning the virus is gone. The differentiation between
functional cures and eradication cures and all the rest
of it, I would worry about using that language. I think
that people understand control better.”
“I think that I might consider dropping the word
cure and changing it to remission, which is a kind
of word that we use in cancers to say ‘I can’t find
your sickness now but it doesn’t mean that I’m
never going to’ and you would have to have follow
up to make sure. Definitely people think that cure
means that it is gone”.
The long time horizon of ‘cure’
In contrast to a simple notion of cure, concepts like re-
mission and suppression also entail an anticipation of
the recurrence of disease. Participants noted that unlike
prevention and treatment, the success of which could
often be measured in days or weeks, the time horizon
for the establishment of cure was potentially very long.
Borrowing again from the concept of ‘remission’, some
participants mentioned the ‘five-year rule’ of remission
and noted that it was vital to remember that unless a
fairly stable and certain cure could be developed, the
concept—and the lived experience—of ‘cure’ was likely
to be dependent on ongoing confirmation of cure:
“I’ve heard people with cancer talk about their
remission as a cure; and yet I would say strictly
speaking doctors would say ‘in remission’ means we
cannot guarantee that it won’t come back.”
For most people, this would play out over a long, pos-
sibly open-ended time horizon and require constant
monitoring.
Lay versions of cure
Participants also noted the ways that the notion of cure
could be understood quite differently outside of biomed-
ical contexts. They described the differing cultural con-
structions of cure that are often at stake in South
African (and many other) contexts. These alternative
notions of cure included both naturalistic forms of cure
(such as local herbal remedies and tonics) as well as
more supernatural forms of cure that involved spiritual
modes of healing. A couple of participants noted, in
addition, that while one could easily find all manner of
local ‘lay’ cures being offered within these context of
traditional, alternative and complementary medicine,
pharmaceutical companies were also engaging in this
discourse. One participant described the ways in which
one drug company was promoting its latest drug’s ability
to tackle the HIV reservoir, an implicit gesture towards
the cure discourse, a claim that this participant argued
was unsupported by the evidence:
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“[A cure] has to be marketed honestly. You know they
have these newer combinations now which talk about
helping reduce the reservoirs of virus……we just don’t
know and there’s not enough evidence”
The multiple and sometimes self-interested meanings
of cure, and the ability of a wide range of actors to trans-
form and use it to their own ends, were noted as an eth-
ical concern in research billed as ‘cure research’.
Cures out of reach
Finally, a couple of participants noted that a cure that
was not affordable or accessible was not really a cure
at all and that researchers and policymakers must be
vigilant in ensuring cure research takes issues of
equity in the distribution of risks and benefits of re-
search seriously.
“… obviously it’s got to be a process that if we do it to
one we can ultimately do it to all; so things like bone
marrow transplants, very invasive things like that are
never going to be the solution, because we can’t ablate
everybody’s bone marrow,… so it would not be
accessible to the… ordinary person in the street …” .
Ethics in HIV cure research
While all of the above themes raise issues that have a
bearing in some way on research ethics in HIV cure re-
search, we also asked participants about specific research
ethics issues related to HIV cure research. Many of the
ethical concerns they raised, while relevant to cure re-
search, were issues that are also applicable to HIV and
medical research more generally. They pointed to the
potentially significant and often unknown harms of new
drugs and medical procedures. They asked questions
about whether, how, and when to include children and
other vulnerable groups in research. They argued for
the importance of operational and community-
oriented research to support implementation of poten-
tial cure modalities. They were concerned about the
potential inequity of the distribution of cure research
risks and benefits (especially between the global North
and South). And as noted above, they highlighted the
difficulty of negotiating truly informed consent in
medical research, especially in contexts with low levels
of health literacy and/or high levels of distrust in bio-
medicine and academic research as is often the case in
South Africa.
We were especially interested, however, in finding out
what participants considered to be the ethical issues that
were either unique to, intensified by, or complicated by
cure research in particular. Four key issues emerged:
Managing potentially unrealistic expectations and avoiding
curative misconception
Like therapeutic misconception that often arises in the
context of treatment trials and other research, curative
misconception could occur in HIV cure trials. Partici-
pants noted the critical importance of avoiding curative
misconception as ‘cure’ research is at a very early stage
of research (which means that almost no one should
have any expectation of individual benefit, unlike in later
phase trials):
“I think it’s got to be explained really carefully that
there’s no guarantee. The place we have seen a
parallel to this is in prevention research. ‘So we’re
giving you a tablet…but…it’s a placebo controlled
trial so we’ve got no way of guaranteeing that this
is going to work or even that you’re on an active
drug. So you’ve got to put in all the other
safeguards of safer sexual practices’. Because the
last thing you want to do is [for] someone to trust
in something that hasn’t yet been proven”
Some participants highlighted the potential risk of
cancer, damage to the immune system, activating previ-
ously dormant virus and other unknowns.
“People need to understand they are taking a
significant risk”.
Another aspect is behavioural disinhibition or risk com-
pensation, which has parallels in prevention research.
“In terms of risk compensation, that will happen
whenever there is any new technology. Well, if it works,
it is extremely difficult to get people to believe that,
you know they’ve gone through some procedure, plus
you are still insisting that they use condoms, for
example. In a way it does create what we as
psychologists call ‘cognitive dissonance’ – these
conflicting ideas.
Psychological toll of long-term medical surveillance
Several participants described in some detail the psycho-
logical toll of long-term medical surveillance—for recur-
rence of an illness, for a diagnosis, or for treatment
failure—and argued that cure research both heightened
the stakes involved while also lengthening the time hori-
zon required by research.
“Failure might be after 5 years of suppression…That
anxiety of coming in all the time for your blood tests
and monitoring…it will be a very interesting period for
people who have to go through that. The emotional
highs and lows will be rollercoaster.”
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Potential difficulties in understanding concepts of latent
infection and the HIV reservoir
As we have noted earlier, there were concerns about the
potential difficulties in understanding concepts of latent
HIV infection and the HIV reservoir, and suggestions
that 1) research participants be well prepared, and prop-
erly counselled and supported during the study, and 2)
studies use more limited and specific language to frame
their research objectives:
“The distinction between a functional cure and
eradication is difficult and the word “control” is
probably better. When researchers talk about cure,
participants might think that the virus is gone. This
would be bad. For instance, with herpes and
chickenpox we don’t use the word cure.”
Treatment interruption
Finally, a widely shared concern among the participants
was the likelihood that HIV cure research would re-
quire people who are stable on ART to stop their treat-
ment as part of HIV cure research, and then resume it
at a later date:
“I’m sure people who are living with HIV…would be
interested in trying out something but…the question
is…whether during the time they have to stop taking
their ARVs – that might be a bit of a concern. I’m
actually trying to figure out how one would do it …
ethically because we know ARVs…enable one to
control or manage the condition.”
There were concerns that this might interrupt estab-
lished routines of treatment adherence, allow time for
the HIV reservoirs to grow in size, increase the risk of
resistance and onward transmission, and possibly cause
unforeseen medical complications such as a higher inci-
dence of cardiovascular disease as observed in the
SMART trial. Similar concerns around treatment inter-
ruption were raised by healthcare providers and patients
in an earlier study [42] and based on our collective
experience in HIV research in South Africa, we believe
these concerns will be valid in future cure research.
Discussion
HIV cure research is complex. Consequently scientific,
ethical and social challenges are anticipated. From the
perspective of HIV researchers, clinicians and activists in
this study it was evident that concerns filtered down
from broad policy issues to practical concerns that will
impact more directly on patients and potential research
participants. At a macro-level two major concerns exist
– the power asymmetry between the global North and
South and the relationship of cure to treatment and pre-
vention research.
It is clear that concerns exist over the current predom-
inance of the global North in setting the cure agenda, the
disproportionate funding available to resource rich set-
tings and the lack of scalability of current cure strategies
for Africa [46, 47]. This concern about the unequal rela-
tionship is a long-standing ethical and political concern
with respect to HIV research and intervention in resource
depleted settings. The absence of the voice of the commu-
nity in setting cure agendas is also palpable. Campbell et
al. have previously commented that “health-related experi-
ences and worldviews of grassroots communities….were
subordinated to the imperatives of international experts
and funders using western, individual-focused biomedical
and behavioural models” in the context of HIV research
[48]. Power asymmetries clearly play a role at multiple
levels. Scalability is particularly important in the African
setting where the burden of HIV is enormous. This speaks
directly to ethical concerns around equity in the global
distribution of risks and benefits of HIV cure research. It
is essential for any cure strategy to be translated into
“locally and culturally appropriate discourses and prac-
tices”, for local capacity to be built to sustain cure inter-
ventions beyond funding periods and that health systems
are strengthened in resource poor settings [47].
The synergies and tensions that exist between cure,
treatment and prevention were regarded as a second
broad concern. Although researchers working in cure
and prevention acknowledge the scientific value that
cure is adding to these fields, there was some concern
that resources could be diverted from treatment and
prevention to cure, a concern raised by others several
years ago [8]. While this is not perceived as a threat at
present, it is something to consider for the future.
Moving down the ‘concern funnel’, patient understand-
ing and expectations were highlighted as important con-
siderations in the consent process and the decision to
enrol in future cure trials. Similar challenges in obtain-
ing informed consent for future HIV cure trials in South
Africa have been raised by others [15]. In particular,
explaining the concepts of latent infection and “reser-
voirs” were perceived to be a major challenge in future
consent processes. This is linked to notions of cure,
which might differ considerably from medical scientists,
who might easily distinguish between functional and
sterilizing cures, to patients who may conceive of cure
very differently. Research into local notions of cure, for
example, has highlighted the fact that for many people
in the South African context, cure is often equated with
the resolution of symptoms rather than with the elimin-
ation of viral particles from the body [48].
A note of caution has therefore been advised over the
use of the word cure. HIV clinicians and researchers in
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this study discussed the construction of cure as prob-
lematic on various levels. We concur. In response to
similar concerns, several authors have suggested alterna-
tives such as “remission” or “experiment” [12–14]. The
latter term in particular has been suggested to ensure
that participants do not overestimate the benefits of the
trial. Several authors distinguish between therapeutic
misconception [49, 50] or curative misconception [13]
and therapeutic misestimation [51]. Therapeutic misesti-
mation occurs when participants overestimate the benefits
or under estimate the risks and this can be tolerated, but a
curative misconception would involve the participant
believing that s/he will be cured with the research. This
fundamentally impacts a participant’s decision to enrol in
a trial and s/he may not be making a truly autonomous
decision. This is particularly important if a cure trial
design includes treatment interruption [52–54]. Under
these circumstances, it is important that research partici-
pants fully appreciate the risks including drug resistance,
the risk of transmission to sexual partners, severe primary
infection-like symptoms, reduced CD4 count and in-
creased risk of cardiovascular events and AIDS-related
events [55–58]. Given the history of illegitimate HIV
“cures” in South Africa and the complexity of HIV cure
language and concepts, we support the concern expressed
by HIV experts in South Africa regarding consent pro-
cesses for future cure research. Nothing short of an in-
tense community engagement process with attention to
science translation will facilitate authentic consent pro-
cesses in this new field of HIV research.
Ultimately REC members are charged with oversight
of consent processes and must therefore be cognisant of
the challenges in understanding the complexity of cure
science. Consequently RECs must be adequately consti-
tuted with appropriate scientific and community expert-
ise [11]. Both RECs and researchers have an obligation
to ensure that the information in consent forms does
not raise undue expectations.
This study sought to establish the views of prominent
HIV experts in South Africa working in the field of re-
search, treatment or activism. There are, however, many
other HIV clinicians working in public health clinics in
South Africa and some of their views must also be cap-
tured. This will be attempted in the next phase of this
study where the views of other stakeholders, including
HIV infected patients will be explored. Likewise the
views of policy makers, private health care funders, the
pharmaceutical industry, traditional healers, health econ-
omists, patients, religious leaders and the media remain
to be explored. The need for early stakeholder engage-
ment has been echoed by others [40, 52].
Future research opportunities exist to explore inter-
national collaborations dealing with cure and how re-
search agendas are being set. South African researchers
and clinicians have a wealth of experience and expertise
in HIV research and care. Consequently, they ought to
be playing a greater role in setting cure agendas.
Conclusions
A holistic approach integrating biomedical treatment,
prevention and cure research is critical to control the
HIV epidemic. It was encouraging to note the desire for
synergy in these three domains amongst researchers and
clinicians. However, the social and ethical dimensions of
cure must also taken into account. HIV experts in this
study appropriately raised concerns about the domin-
ance of the global North in driving the cure research
agenda and the absence of civil society voices in shaping
cure research priorities and future access. The call for
global equity in driving the HIV cure research agenda is
a call to ensure a fair distribution of risks and benefits
between the global North and South. Scientists and
clinicians raised valid concerns about the various con-
structs of cure and translation of complex HIV cure sci-
ence into lay language to enhance consent processes.
This is an important consideration in South Africa
where consent processes are challenging for less com-
plex research. Likewise, it is an ethical obligation for
RECs to be adequately constituted with scientific expert-
ise and community representation when reviewing cure
protocols. It is hoped that knowledge and resource shar-
ing in the context of collaboration between research sci-
entists working in cure and those working in treatment
and prevention will accelerate progress towards cure.
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